Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$105.66
-2.5%		$105.04
$81.97
▼
$137.49
$187.45B0.597.19 million shs11.40 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$84.53
-3.8%		$81.95
$54.11
▼
$92.59
$33.17B1.423.69 million shs8.22 million shs
HealthEquity, Inc. stock logo
HQY
HealthEquity
$93.36
-2.8%		$99.59
$72.76
▼
$107.62
$7.95B0.22841,221 shs872,971 shs
Insulet Corporation stock logo
PODD
Insulet
$142.28
-3.5%		$154.04
$126.40
▼
$354.88
$10.23B1.081.53 million shs2.23 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-2.43%-2.94%-2.00%+18.51%-20.12%
DexCom, Inc. stock logo
DXCM
DexCom
-3.83%-6.22%-0.26%+13.05%+8.37%
HealthEquity, Inc. stock logo
HQY
HealthEquity
-2.82%-3.75%-10.77%+4.06%+0.32%
Insulet Corporation stock logo
PODD
Insulet
-3.53%-4.11%+0.79%-5.59%-59.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$105.66
-2.5%		$105.04
$81.97
▼
$137.49
$187.45B0.597.19 million shs11.40 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$84.53
-3.8%		$81.95
$54.11
▼
$92.59
$33.17B1.423.69 million shs8.22 million shs
HealthEquity, Inc. stock logo
HQY
HealthEquity
$93.36
-2.8%		$99.59
$72.76
▼
$107.62
$7.95B0.22841,221 shs872,971 shs
Insulet Corporation stock logo
PODD
Insulet
$142.28
-3.5%		$154.04
$126.40
▼
$354.88
$10.23B1.081.53 million shs2.23 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-2.43%-2.94%-2.00%+18.51%-20.12%
DexCom, Inc. stock logo
DXCM
DexCom
-3.83%-6.22%-0.26%+13.05%+8.37%
HealthEquity, Inc. stock logo
HQY
HealthEquity
-2.82%-3.75%-10.77%+4.06%+0.32%
Insulet Corporation stock logo
PODD
Insulet
-3.53%-4.11%+0.79%-5.59%-59.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.96
Moderate Buy$119.5013.10% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.92
Moderate Buy$88.714.94% Upside
HealthEquity, Inc. stock logo
HQY
HealthEquity
2.85
Moderate Buy$111.8719.82% Upside
Insulet Corporation stock logo
PODD
Insulet
2.44
Hold$195.4037.33% Upside

Current Analyst Ratings Breakdown

Latest DXCM, HQY, PODD, and ABT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$135.00
9/3/2026
HealthEquity, Inc. stock logo
HQY
HealthEquity
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy
9/2/2026
HealthEquity, Inc. stock logo
HQY
HealthEquity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
8/31/2026
HealthEquity, Inc. stock logo
HQY
HealthEquity
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$135.00 ➝ $142.00
8/28/2026
HealthEquity, Inc. stock logo
HQY
HealthEquity
Telsey Advisory Group logo
Telsey Advisory Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$111.00
8/28/2026
HealthEquity, Inc. stock logo
HQY
HealthEquity
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/28/2026
HealthEquity, Inc. stock logo
HQY
HealthEquity
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$115.00
8/25/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$115.00 ➝ $135.00
8/13/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$130.00
8/11/2026
DexCom, Inc. stock logo
DXCM
DexCom
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/6/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$44.33B4.12$6.82 per share15.50$30.35 per share3.48
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B6.84$2.66 per share31.75$7.04 per share12.01
HealthEquity, Inc. stock logo
HQY
HealthEquity
$1.36B5.67$5.13 per share18.21$24.06 per share3.88
Insulet Corporation stock logo
PODD
Insulet
$2.71B3.64$6.10 per share23.33$21.54 per share6.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$6.52B$3.0934.1917.382.0111.65%17.69%9.44%10/21/2026 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.5333.4127.441.4720.12%35.94%14.75%10/29/2026 (Estimated)
HealthEquity, Inc. stock logo
HQY
HealthEquity
$215.20M$2.7733.7020.211.5217.36%15.33%9.51%N/A
Insulet Corporation stock logo
PODD
Insulet
$247.10M$5.3526.5918.481.1612.29%29.29%13.31%11/5/2026 (Estimated)

Latest DXCM, HQY, PODD, and ABT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2026Q2 2027
HealthEquity, Inc. stock logo
HQY
HealthEquity
$1.19$1.24+$0.05$0.78$349.22 million$350.73 million
8/5/2026Q2 2026
Insulet Corporation stock logo
PODD
Insulet
$1.47$1.66+$0.19$1.37$787.39 million$801.70 million
7/30/2026Q2 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.6110$0.70+$0.0890$0.64$1.29 billion$1.31 billion
7/16/2026Q2 2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.28$1.31+$0.03$0.53$12.52 billion$12.59 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.522.38%+10.39%81.55%54 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
HealthEquity, Inc. stock logo
HQY
HealthEquity
N/AN/AN/AN/AN/A
Insulet Corporation stock logo
PODD
Insulet
N/AN/AN/AN/AN/A

Latest DXCM, HQY, PODD, and ABT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/12/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.632.82%7/15/20267/15/20268/17/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.57
1.38
0.97
DexCom, Inc. stock logo
DXCM
DexCom
0.47
1.73
1.43
HealthEquity, Inc. stock logo
HQY
HealthEquity
0.47
2.99
2.99
Insulet Corporation stock logo
PODD
Insulet
0.65
2.48
1.83

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
HealthEquity, Inc. stock logo
HQY
HealthEquity
99.55%
Insulet Corporation stock logo
PODD
Insulet
N/A

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
HealthEquity, Inc. stock logo
HQY
HealthEquity
1.60%
Insulet Corporation stock logo
PODD
Insulet
0.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.73 billion1.72 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000377.36 million376.30 millionOptionable
HealthEquity, Inc. stock logo
HQY
HealthEquity
2,81482.72 million81.39 millionOptionable
Insulet Corporation stock logo
PODD
Insulet
5,40069.35 million69.10 millionOptionable

Recent News About These Companies

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
September 8 at 10:26 AM  |  zacks.comhttps://www.zacks.com/stock/news/2986263/is-it-prudent-to-retain-insulet-stock-in-your-portfolio-for-now?cid=cs-stocknewsapi-ft-analyst_blog|rank_focused-2986263
Insulet (PODD) is a Top-Ranked Value Stock: Should You Buy?
September 7 at 10:40 AM  |  zacks.comhttps://www.zacks.com/stock/news/2985753/insulet-podd-is-a-top-ranked-value-stock-should-you-buy?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_value_score-2985753
Nykredit A S Purchases Shares of 35,795 Insulet Corporation $PODD
September 7 at 5:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-purchases-shares-of-35795-insulet-corporation-podd-2026-09-07/
AXQ Capital LP Trims Position in Insulet Corporation $PODD
September 7 at 3:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-axq-capital-lp-trims-position-in-insulet-corporation-podd-2026-09-07/
Insulet Corporation $PODD Shares Sold by Munich Reinsurance Co Stock Corp in Munich
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-insulet-corporation-podd-shares-sold-by-munich-reinsurance-co-stock-corp-in-munich-2026-09-05/
Public Employees Retirement System of Ohio Makes New Investment in Insulet Corporation $PODD
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-makes-new-investment-in-insulet-corporation-podd-2026-09-05/
Insulet Corporation (NASDAQ:PODD) Receives Consensus Recommendation of "Hold" from Brokerages
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-insulet-corporation-nasdaq-podd-receives-consensus-recommendation-of-hold-from-brokerages-2026-09-05/
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?
September 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2985357/why-is-insulet-podd-up-8-1-since-last-earnings-report?cid=cs-stocknewsapi-ft-realtime_blog-2985357
Insulet Corporation $PODD Shares Purchased by denkapparat Operations GmbH
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-insulet-corporation-podd-shares-purchased-by-denkapparat-operations-gmbh-2026-09-04/
Unpacking Q2 earnings: Insulet (NASDAQ:PODD) in the context of other patient monitoring stocks
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/technology/hardware-and-devices/unpacking-q2-earnings-insulet-nasdaq-podd-in-the-context-of-other-patient-monitoring-stocks/ar-AA2bvoiQ
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Holdings in Insulet Corporation $PODD
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-decreases-holdings-in-insulet-corporation-podd-2026-09-02/
39,965 Shares in Insulet Corporation $PODD Acquired by The Manufacturers Life Insurance Company
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-39965-shares-in-insulet-corporation-podd-acquired-by-the-manufacturers-life-insurance-company-2026-09-01/
Insulet stock faces legal deadline as investors weigh class action risk
August 31, 2026  |  ad-hoc-news.deA
PODD DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026
August 31, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260831760201/en/podd-deadline-tonight-faruqi-faruqi-llp-reminds-insulet-podd-investors-of-securities-class-action-lawsuit-deadline-on-august-31-2026/
PODD DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important August 31 Deadline in Securities Class Action - PODD
August 31, 2026  |  newsfilecorp.comN
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm
August 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353559/9788/en/bronstein-gewirtz-grossman-llc-urges-insulet-corporation-investors-to-act-class-action-filed-alleging-investor-harm.html
Levi & Korsinsky Reminds Insulet Corporation Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 31, 2026 - PODD
August 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353453/3080/en/levi-korsinsky-reminds-insulet-corporation-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-31-2026-podd.html
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law
August 31, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260831864137/en/podd-investors-have-opportunity-to-lead-insulet-corporation-securities-fraud-lawsuit-with-sbs-law/
Rakuten Investment Management Inc. Makes New $1.79 Million Investment in Insulet Corporation $PODD
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-rakuten-investment-management-inc-makes-new-179-million-investment-in-insulet-corporation-podd-2026-08-31/
Insulet Corporation $PODD Shares Purchased by Headlands Technologies LLC
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-insulet-corporation-podd-shares-purchased-by-headlands-technologies-llc-2026-08-31/
Insulet Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PODD
August 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/insulet-corporation-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--podd-302864538.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$105.66 -2.68 (-2.47%)
Closing price 09/8/2026 03:59 PM Eastern
Extended Trading
$105.65 0.00 (0.00%)
As of 09/8/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

DexCom stock logo

DexCom NASDAQ:DXCM

$84.53 -3.37 (-3.83%)
Closing price 09/8/2026 04:00 PM Eastern
Extended Trading
$84.01 -0.52 (-0.62%)
As of 09/8/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

HealthEquity stock logo

HealthEquity NASDAQ:HQY

$93.36 -2.71 (-2.82%)
Closing price 09/8/2026 04:00 PM Eastern
Extended Trading
$93.23 -0.13 (-0.14%)
As of 09/8/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

Insulet stock logo

Insulet NASDAQ:PODD

$142.28 -5.20 (-3.53%)
Closing price 09/8/2026 04:00 PM Eastern
Extended Trading
$143.14 +0.86 (+0.60%)
As of 09/8/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas